A Study to Determine the Effects of Blocking the Receptors of GLP-1 on Appetite after Bariatric Surgery

Overview

About this study

The purpose of this study is to determine the effects of blocking the receptors of the Glucagon-like Peptide-1 (GLP-1) hormone after different types of bariatric surgery on the regulation of food intake and appetite control.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Has undergone either sleeve gastrectomy or Roux-en-Y Gastric Bypass surgery within prior 2 years
Healthy, with no active systemic illness

Exclusion Criteria

Pregnancy
Functional or organic bowel symptoms
Systemic illness
Diabetes
Bariatric surgery > 2 years

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Adrian Vella, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials